AstraZeneca plc (AZN.L, AZN) said that its gastric cancer treatment Lynparza or olaparib in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival or OS in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.
from RTT - Biotech http://ift.tt/1Tn6lSR
via IFTTT
No comments:
Post a Comment